Category: News

5th Annual Science Meeting

October 10-11th 2018
British Medical Association House, Central London
Come and join the bioprocessing community at our 5th Annual Science meeting.
A wait list is now in place

“The 2017 meeting was one of the most interesting and educational that I have attended in a while!”

Wednesday October 10th
9.30 Registration
10.15-10.30 Welcome, achievements and what for BioProNET
Designing more efficient cell-expression systems
10.30-10.55 Kerstin Otte
 University of Applied Science Biberach, Germany Identification and characterisation of intracellular production bottlenecks in CHO cells producing complex biopharmaceuticals
10.55-11.20 Colin Robinson University of Kent Development of next generation E. coli platforms for the regulated production and periplasmic targeting of biotherapeutics 
11.20-11.30 Andrew Peden  University of Sheffield Developing a toolkit for determining the manufacturability of new therapeutics in CHO cells 
11.30-11.55 Nathan Lewis – University of California San Diego, USA Engineering CHO cells with enhanced traits with multiplex genome editing
11.55-12.05 Invited short talk

12.05-13.15 Lunch

Building expression systems into optimised process
13.15-13.40 Gary FinkaGlaxoSmithKline Developing a next-generation cell line development platform through targeted automation, analytics and informatics
13.40-14.05 Sophia Hober Royal Institute of Technology, Sweden The human secretome project
14.05-14.15 Gary Montague Teesside University Improved preservation of biologics by continuous intensified lyophilisation
14.15-14.40 Tarit Mukhopadhyay University College London Manufacturing the future at less than a $1 a dose and meeting global health needs
14.40–15.05 Natalio Krasnogor Newcastle University Synthetic portabolomics: bridging the gap between the lab bench and industry to speed up the development of new biotech products

15.05-15.45 refreshment break and networking

The clinic and beyond
15.45-16.10 Caroline Barelle Elasmogen soloMERä Biologics: Site-specific therapeutic biologics for the treatment of inflammatory disease
16.10-16.35 Phil Cater Leaf Expression Systems Plant produced biologics – process economics
16.35-16.45 Michael Plevin University of York Can an archaeal helicase enhance the performance of a nanopore DNA sequencer?
16.45-16.55 Invited short talk

Hotel check-in
18.30 Poster session
20.00 Conference dinner

Thursday October 11th
Upstream meets downstream – rapid process development
9.00-9.25 Paul Dalby University College London New analytical methods for chromatography; further downstream to formulation
9.25-9.50 Yvonne Genzel Max Planck Institute for Dynamics of Complex Technical Systems, Germany Intensified cell-based viral vaccine processes: from continuous to perfusion and to hybrid systems
9.50-10.15 Martyn Hulley MedImmune Nucleic acid purification for biotherapeutics
10.15-10.25 Dave Brockwell University of Leeds Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
10.25-10.35 Invited short talk
10.35-10.45 Pernille Harris Technical University of Denmark Solution structure and self-association of pharmaceutical proteins

11.00-11.40 refreshment break and networking

Molecular characterisation of process quality
11.40-12.05 Mike Betenbaugh Johns Hopkins University, USA Glycoengineering of mammalian cell lines to improve product quality
12.05-12.30 Laura Palomares National Autonomous University of Mexico Challenges of bringing recombinant vaccines to the market: A case study for a influenza vaccine
12.30-12.40 Perdita Barran University of Manchester Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
12.40-12.50 Invited short talk
12.50-13.15 Jonathan Bones The National Institute for Bioprocessing Research and Training, Ireland Characterisation of biopharmaceuticals using intact protein separations hyphenated to high resolution native mass spectrometry

13.15-14.00 Poster prizes and lunch
14.00-16.00 Optional collaboration-building session

Timings may change due to logistical needs

waiting list:

Screen Shot 2017-10-25 at 16.12.18

Industrial Strategy boost for UK medicine manufacturing

New initiatives to accelerate the development and manufacture of new medicines have been awarded funding from Innovate UK under the Industrial Strategy Challenge Fund. In total, 22 projects involving 58 organisations will get £15 million.

It’s great to see many of our member companies and universities being very successful and a diverse range of projects that fall within BioProNET remit!

Examples include:
University College London – Design, transfer and qualification of a commercially-scalable process for viral vectors
Synpromics and Lonza Biologics – Development of a novel inducible expression system for the manufacture of therapeutic proteins from CHO cells.
Ipsen Biopharm, CPI and Torchlight Genetics – Novel production process for a highly potent recombinant protein using doggybone DNA (dbDNA) vector and cell free expression technology

A full list of funded projects can be found here.


2018 Science Meeting prize winners

Screen Shot 2017-11-15 at 16.37.51

Conratulations to the winners of the poster and short talk prizes at our 4th annual science meeting, who received their prizes from Karen Lewis of the BBSRC (far left).

The winners were Rochelle Aw, Imperial College London – 1st prize talk (pictured 2nd left); Eva Pekle, MedImmune & Univserity of Kent – 2nd prize talk (pictured middle); Tania Selas Castiñeiras, Cobra Biologics – 3rd talk prize; Hirra Hussain, University of Manchester – 1st prize poster, Natalie Talbot, University of Kent – 2nd prize poster (pictured 2nd right) and James Budge, University of Kent – 3rd poster prize (pictured far right).

IBSCA funding awarded

BioProNET has recently awarded six indistrial biotecnology seeding catalyst awards (IBSCA). This funding aims to develop and progress ideas and technology within the scope and remit of BioProNET and the call along the technology readiness level (TRL) pathway.

Pilot production of engineered nucleases with applications in molecular biology and diagnostic devices
Jon Sayers, University of Sheffield

Optimization of influenza vaccine manufacturing through inhibition of autophagy
Jeremy Rossman, University of Kent

Improved microfluidic devices for downstream bioprocess separation of sub-micron targets
Alan Goddard, Aston University

Learning from charge interactions in nature to understand poly-anion/cation complementarity in drug encapsulation
Jim Warwicker, University of Manchester

Engineering secretory capacity in S. cerevisiae strains to improve recombinant protein production yield
Campbell Gourley, University of Kent

Enhancing secretory pathway function to allow selection of host cell clones
Lisa Swanton, University of Manchester

Establishing a prototype process for manufacturing non‐therapeutic biologics expressed in plants for the R&D market
Anil Day, University of Manchester

BioProNET BIV and PoC funding awarded

Congratulations to the awardees of funding in our most recent call for business interaction vouchers and proof of concept funding:

Proof of concept funding:
Improved preservation of biologics by continuous intensified lyophilisation
Gary Montague, Teeside University; Lonza, Glythera, Accelyo
This project proposes to perform experimental trials of model biologics using laboratory-scale continuous intensified lyophilisation, a technology that uses intensified controlled rate freezing followed by continuous sublimation, to investigate whether this improves activity.

Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
David Brockwell, University of Leeds; Cobra Biologics
Here we aim to find whether a device we developed — that can identify ‘bioprocessible’ protein therapeutics and to optimize buffer conditions — can also inform gene therapy viral vector development or as an analytical tool to differentiate between vectors with empty or full payloads.

Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
Perdita Barran, University of Manchester; Covance

Our aim is to characterize the primary sequence, to locate and analyse PTMs and to assess the three-dimensional structure and extent of aggregation of biopharmaceuticals as quickly as possible using direct mass analysis of native proteins directly from crude cell lysates, without any prior purification.

Business interaction vouchers:
Comparing the productivity of three cell-free extracts based on industrial cell lines
Karen Polizzi, Imperial College London; Lonza
It is unclear how much variability there is between cell-free systems produced from different cell lines. This project aims to compare cell-free systems made from three industrial cell lines to understand how much their protein production capabilities vary.

Scale up of vaccine production in a microalgal host for animal trials
Saul Purton, University College London; MicrosynbiotiX
We will examine the pilot scale production, harvesting and recovery of Chlamydomonas reinhardtii biomass that has been engineered to express a vaccine against a major fish pathogen, with the goal of producing sufficient dried algal material for formulation into fish-feed and use in challenge trials.

Click here for a list of all the proof of concept funding and busines interaction vouchers that we’ve awarded.